Apogee Therapeutics, Inc.
APGE
Classifica tra le azioni
#2350
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Prezzo delle azioni
$135.07
Ultima sincronizzazione: 2026-09-04
Capitalizzazione di mercato
$8.36B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
137.21%
Paese
US
Scambia Apogee Therapeutics, Inc. (APGE)
Categoria
Healthcare
Rapporto P/S per Apogee Therapeutics, Inc. (APGE)
Rapporto P/S al October 2026 TTM: 0.00
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Apogee Therapeutics, Inc., il rapporto P/S attuale (TTM) è 0.00. Alla fine del 2023, era pari a 0.00.
Storico del rapporto P/S per Apogee Therapeutics, Inc. da 2022 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
